In licensed markets, Eurofins CDMO provides phytocannabinoid development and manufacturing services via synthetic routes. We also provide reference standards for a wide variety of phytocannabinoids.
We employ rigorous API development expertise to produce well-characterised synthetic phytocannabinoids and reference standards of high purity, which are not readily achieved through traditional extraction involving cannabis plants or seeds.
Our capabilities:
We employ innovative formulation and manufacturing technologies for bioavailability enhancement and stability improvement of cannabinoids (CBD & THC), with patient compliant dosage forms (mini tablets, sublingual, buccal, gums) as the ultimate goal.
Our capabilities:
Reference standards preparation
We offer the following Phytocannabinoid Reference Standards at milligram to gram quantities.
Compound Purity (a/a% HPLC)
Cannabidiol (CBD) ≥99
Cannabidibutol (CBDB) ≥97
Cannabidivarin (CBDV) ≥99
9-Tetrahydrocannabinolvarin (THCV) ≥98
Cannabinol (CBN) ≥99
Cannabidiolic Acid (CBDA) ≥99
Impurity Standards ≥95-99
